Interleukin 17A Promotes Lymphocytes Adhesion and Induces CCL2 and CXCL1 Release from Brain Endothelial Cells

Int J Mol Sci. 2017 May 8;18(5):1000. doi: 10.3390/ijms18051000.

Abstract

The nature of the interaction between Th17 cells and the blood-brain barrier (BBB) is critical for the development of autoimmune inflammation in the central nervous system (CNS). Tumor necrosis factor alpha (TNF-α) or interleukin 17 (IL-17) stimulation is known to enhance the adherence of Th17 cells to the brain endothelium. The brain endothelial cells (bEnd.3) express Vascular cell adhesion molecule 1 (VCAM-1), the receptor responsible for inflammatory cell adhesion, which binds very late antigen 4 (VLA-4) on migrating effector lymphocytes at the early stage of brain inflammation. The present study examines the effect of the pro-inflammatory cytokines TNF-α and IL-17 on the adherence of Th17 cells to bEnd.3. The bEnd.3 cells were found to increase production of CCL2 and CXCL1 after stimulation by pro-inflammatory cytokines, while CCL2, CCL5, CCL20 and IL17 induced Th17 cell migration through a bEnd.3 monolayer. This observation may suggest potential therapeutic targets for the prevention of autoimmune neuroinflammation development in the CNS.

Keywords: Th17 cells; VCAM-1; blood–brain barrier; chemokines; multiple sclerosis; neuroinflammation.

MeSH terms

  • Animals
  • Blood-Brain Barrier / cytology
  • Blood-Brain Barrier / metabolism*
  • Cell Adhesion*
  • Cell Line
  • Cells, Cultured
  • Chemokine CCL2 / metabolism*
  • Chemokine CXCL1 / metabolism*
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Female
  • Interleukin-17 / pharmacology*
  • Mice
  • Th17 Cells / drug effects
  • Th17 Cells / physiology*
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Chemokine CCL2
  • Chemokine CXCL1
  • Interleukin-17
  • Tumor Necrosis Factor-alpha